Tag:

Eli Lilly

Latest Headlines

Latest Headlines

With peglispro shunted aside, Lilly could go full-tilt after Lantus

Eli Lilly's long-acting basal insulin peglispro is on the back burner now. Some analysts figure it's well on its way to being canned. But the news isn't quite as bad for Lilly as one might expect--nor quite as good for the drug peglispro was hoping to challenge, Sanofi's Lantus.

Is a weak Eli Lilly ripe for a takeover?

Everybody sees something different when they look at Eli Lilly, which has recently dropped out of the top 10 pharma group. A number of analysts, some with good reason to shine up to CEO John Lechleiter, see a company that has hit bottom and is on the comeback trail, with new drug approvals to help bolster Lechleiter's bullish forecasts.

Lilly's new insulin is likely DOA after latest delay, analyst says

Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting off a potential regulatory filing by a year or more and leading a top analyst to eulogize the program.

Lilly extends study of highly anticipated cholesterol fighter

Eli Lilly says it will extend the massive Phase III trial for its highly anticipated drug candidate evacetrapib, a CETP inhibitor that works to lower LDL, or "bad," cholesterol levels and raise HDL, or "good," cholesterol levels, by 6 months.

Lilly delays its high-risk 'good' cholesterol trial with IMPROVE-IT in mind

Eli Lilly is extending its massive Phase III trial on a new cardio drug by 6 months in what the company says is a reaction to some recent developments in science.

Veterinary trade group denounces press reports of alleged conflicts of interest

One major news organization suggesting improper actions by members of your profession is bad enough; two is downright painful--and possibly unjustified. That's the message from Ted Cohn, president of the American Veterinary Medical Association, who has officially denounced what he calls a series of "attack" articles on veterinarians that allege their relationships with drug companies are unethical.

Struggling Lilly, AbbVie may find Low-T boost from specialized testosterone clinics

After a year of regulatory warnings and safety debates over "Low T" drugs, it's no surprise that drugmakers like Eli Lilly and AbbVie expect their testosterone sales to suffer in 2015. But as the mainstream medical community apparently moves away from testosterone replacement meds, specialized clinics are taking up the charge.

Niche Low-T lifestyle clinics might give suffering Lilly, AbbVie meds a boost

After a year of regulatory warnings and safety debates over "Low T" drugs, it's no surprise that drugmakers like Eli Lilly and AbbVie expect their testosterone sales to suffer in 2015. But as the mainstream medical community apparently moves away from testosterone replacement meds, specialized clinics are taking up the charge.

Moody's: Big Pharmas face growing patent-loss threats, but some pipelines are improving

For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.

Sanofi, Roche and Lilly help bankroll a $20M round for Parkinson's player LTI

Kees Been has banked the $20 million round needed to move a bold new development program for delaying or preventing Parkinson's toward the clinic. And the veteran biotech CEO at the helm of Lysosomal Therapeutics Inc. is moving forward with a group of high-profile backers in his corner.